The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Antimicrobials and Antiepileptics Are the Leading Causes of Idiosyncratic Drug‐induced Liver Injury in American Children
Abstract
Objectives: The aim of this study was to provide an overview of the presenting features, etiologies, and outcomes of children enrolled in the Drug‐induced Liver Injury Network (DILIN) prospective and retrospective studies. Methods: Consecutive definite, highly likely, or probable cases in children enrolled into the ongoing DILIN prospective and retrospective studies between September 2004 and February 2017 were reviewed. Results: Fifty‐seven cases were adjudicated as definite (14), highly likely (30), or probable (13) DILI. Median age was 14.3 years (1.7–17.9), 67% female, and 82% Caucasian. At DILI onset, 82% had hepatocellular injury with a median alanine aminotransferase of 411 U/L (33–4185), alkaline phosphatase 203 U/L (62–1177), and total bilirubin 3.3 mg/dL (0.2–33.9). The median duration of suspect medication use was 55 days (1–2789) and the most frequently implicated individual agents were minocycline (n = 11) and valproate (n = 6). Sixty‐three percent were hospitalized and 3 (5%) underwent liver transplant within 1 month of DILI onset. Among 46 children followed for at least 6 months, 8 (17%) met criteria for chronic DILI with 6 of them having persistent liver injury at 24 months of follow‐up. A genome‐wide association study in 39 Caucasian children focusing on regions associated with pediatric cholestatic liver disease failed to demonstrate any single nucleotide polymorphism associated with DILI susceptibility or outcome. Conclusions: Antimicrobials (51%) and antiepileptic drugs (21%) are the most frequently implicated agents in pediatric DILI patients. Although the majority of cases are self‐limited, there is potential for serious morbidity including acute liver failure, chronic liver injury, and death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In pediatric medicine, DILI is rare but has high morbidity and mortality and is one of the most common causes of acute liver failure; diagnosis is challenging due to low incidence and phenotypic variability.
“In pediatric medicine, DILI is a rare clinical situation. However, it has high morbidity and mortality, and it is one of the most common causes of acute liver failure. Furthermore, its diagnosis is clinically challenging due to its low incidence and phenotypic variability [6,7,8].”
From Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM (2023) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A reference panel of 64,976 haplotypes for genotype imputation
the Haplotype Reference Consortium (2016) · Nature Genetics · doi:10.1038/ng.3643 · Cited by 2,836
Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Flagged first, then by citations
Research works printed but not linked: 30
- 10.1053/jhep.2002.34857 · DOI · Paper page
- 10.1017/CBO9781139012102.005 · DOI
- 10.1093/jpids/piu037 · DOI
- MulderRL vanDalenEC Van den HofM et al. Hepatic late adverse effects after antineoplastic treatment for childhood cancer.Cochrane Database Syst Rev2011;CD008205. · DOI
- 10.1002/hep.30176 · DOI
- 10.2165/00002018-200932010-00005 · DOI · Paper page
- 10.1053/j.gastro.2016.12.016 · DOI · Paper page
- 10.1053/j.gastro.2011.04.001 · DOI · Paper page
- 10.1016/j.jhep.2017.03.010 · DOI · Paper page
- 10.1097/MPG.0b013e31821d6cfd · DOI
- 10.1002/hep.23577 · DOI · Paper page
- 10.1016/0895-4356(93)90101-6 · DOI · Paper page
- 10.1002/hep.26709 · DOI · Paper page
- 10.1038/ng.3656 · DOI · Paper page
- 10.1086/519795 · DOI · Paper page
- 10.1002/hep.28779 · DOI
- 10.1002/hep.23891 · DOI
- 10.1053/j.gastro.2015.03.006 · DOI · Paper page
- 10.1007/s10620-016-4121-6 · DOI
- 10.1002/hep.22895 · DOI · Paper page
- 10.1542/peds.2013-0490B · DOI
- 10.1016/j.clinbiochem.2013.06.012 · DOI
- 10.1371/journal.pone.0108970 · DOI
- 10.1038/clpt.2011.47 · DOI
- 10.1016/j.seizure.2010.01.002 · DOI
- 10.1016/S2210-7401(12)70018-9 · DOI
- 10.1002/hep.23539 · DOI
- Adeli KCF, 2018, Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 1745
- 10.1373/clinchem.2015.240523 · DOI
- 10.1373/clinchem.2011.177741 · DOI · Paper page
Cited by
Sorted by citations
ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., & Fontana, R. J. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.131 · Cited by 860
Self-citationACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
Chalasani, N. P., Maddur, H., Russo, M. W., Wong, R. J., Reddy, K. R., & on behalf of the Practice Parameters Committee of the American College of Gastroenterology (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001259 · Cited by 430
Self-citationAASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Self-citationAndújar-Vera, F., Alés-Palmer, M. L., Muñoz-de-Rueda, P., Iglesias-Baena, I., & Ocete-Hita, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713562 · Cited by 10
Metadata
- Authors
- DiPaola, F., Molleston, J. P., Gu, J., Cirulli, E. T., Chalasani, N., Barnhart, H., Kleiner, D. E., Hoofnagle, J. H., Fontana, R. J., & US Drug Induced Liver Injury Network
- Affiliations
- University of Michigan Ann Arbor MI
- Indiana University School of Medicine Indianapolis IN
- Duke Clinical Research Institute Duke University Raleigh NC
- National Cancer Institute Bethesda MD
- Liver Diseases Research Branch National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda MD
- Venue
- Journal of Pediatric Gastroenterology and Nutrition
- Publisher
- Wiley
- Published
- 2019-08
- Volume
- 69
- Issue
- 2
- Pages
- 152-159
- ISSN
- 0277-2116
- 1536-4801
- PMC
- PMC6658343
- Cited by
- 36
- References
- 2
- Language
- en
- Funders
- Duke University (U01‐DK065201)
- University of Connecticut (U01‐DK065238)
- Howard Hughes Medical Institute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review